[1] |
LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji.
Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
|
[2] |
LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan.
Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785.
|
[3] |
CAO Kai, QIAN Peipei, GAO Xin, YANG Futian, ZHAO Liang, XU Bingxin, ZHANG Xianjun.
Mining of Risk Signals Adverse Events Related to Drug-Induced Salivary Gland Calculus Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 799-804.
|
[4] |
LI Min, LI Chunlei, SUN Cuicui, YU Wenwen, SUN Qing, QI Yingmei, LIU Anchang.
One Case of Acute Generalized Exanthematous Pustulosis Caused by Abrocitinib Tablets
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 823-825.
|
[5] |
CHEN Lingbin, HUANG Zhixiong, ZHENG Cailin, WU Jinneng, CHEN Zhou.
Adverse Event Signals for Osimertinib-Induced Muscle Toxicity Based on FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 447-451.
|
[6] |
ZHONG Ling, ZENG Huiyan, YUAN Xin, WANG Yingyan.
Adverse Event Signals of Liraglutide and Semaglutide Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 305-312.
|
[7] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[8] |
ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang.
Detection and analysis of signals of adverse events induced by deferasirox based on FAERS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
|
[9] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|
[10] |
GAO Xu, PENG Jin’e, FAN Zibo, ZHANG Wei.
Systematic evaluation of clinical features and prognostic outcomes of rifampicin-induced hemolytic anemia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 671-676.
|
[11] |
SHI Guanhong, WANG Qi, SUN Hao, CHEN Yanjie, CHU Ziyan, JIANG Ao, TANG Zaixiang, LIU Jingfang.
Safety signal analysis of antidepressants use in fetus and neonate based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 687-692.
|
[12] |
WU Yi, HE Jinyang, WANG Xiaojian, ZhOU Xiaozhu, LIU Ranjia, GUO Mingxing, ZHAO Ying, DAI Wendi, CUI Xiangli.
Adverse events of COVID-19 vaccination in recipients of liver and kidney transplant based on US VAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 572-579.
|
[13] |
HAN Li, CHEN Li, CHEN Qian, XIAO Hongtao.
Signal detection of adverse reaction of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 440-446.
|
[14] |
YOU Xiaoyan, ZHENG Yingying, WANG Xianying.
Data-mining and analysis of adverse events signals for infliximab based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 335-340.
|
[15] |
WU Tingxi, ZHAO Zhigang, SHI Yanfeng, ZHANG Yang, ZHANG Yinan, ZHU Bin.
Risk assessment of colchicine-associated neurological adverse events based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 341-345.
|